Dramatic multifocal osteosarcoma treatment response in the setting of POT1 tumor predisposition syndrome

Stephen Gilene1, Kristen D'Aquila2, Brittany Cooper3

  • 1Cincinnati Children's Hospital Medical Center, Division of Oncology, Cincinnati, OH, USA; University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Cancer Genetics
|September 3, 2025
PubMed
Abstract

Insights

POT1 tumor predisposition (POT1-TPD) can cause rare multifocal osteosarcoma. This case showed a POT1-TPD patient achieving long-term remission with chemotherapy, suggesting a unique, treatable phenotype.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • POT1 tumor predisposition (POT1-TPD) is linked to various cancers due to POT1 mutations causing telomere dysfunction and genomic instability.
  • Osteosarcoma, a common bone cancer, has a poor prognosis, especially in multifocal cases.

Observation:

  • A 15-year-old male presented with multifocal osteosarcoma and a POT1 splice site variant (c.949+1G>C) in both germline and somatic cells.
  • Despite widespread disease, the osteosarcoma demonstrated significant sensitivity to standard chemotherapy.

Findings:

  • The patient achieved long-term remission, indicating a potentially unique and favorable phenotype for POT1-TPD-associated multifocal osteosarcoma.
  • Hereditary alterations in telomeric function, including POT1, are increasingly recognized in sarcoma susceptibility.

Implications:

  • This case highlights POT1-TPD as a potential hereditary risk factor for multifocal osteosarcoma.
  • The observed chemosensitivity suggests that POT1-TPD-associated multifocal osteosarcoma may respond well to treatment, offering a better prognosis than previously thought.